KRAS and cancer: Three such drugs (all mAbs) are approved to treat metastatic CRC: cetuximab and panitumumab, which inhibit the epidermal growth factor receptor (EGFR; a member of the ErbB family of receptor tyrosine kinases) and show benefit only for K-RAS wild-type cancers, and bevacizumab, which inhibits the angiogenesis-promoting vascular endothelial growth factor (VEGF) [2].